hysicians entering aesthetic medicine know how to diagnose. The consultation is different — it’s a goals-based conversation, not a problem-solving session. Here’s how to structure one that works.
If you’ve been considering aesthetic medicine, 2026 may be the best entry window in years — a documented provider shortage, a wave of new patients, and a training path that’s more accessible than most providers realize. Here’s the realistic roadmap.
Not all regenerative aesthetics treatments are created equal — and in 2026, the evidence gap between them is wider than most product reps will tell you. Here’s an honest evidence rating for every major regenerative modality, plus a practical framework for talking to patients about what you can and can’t confidently offer.
Patients are arriving at aesthetic and weight management practices asking about NAD+. Here’s the clinical case for IV delivery, what the evidence actually shows, and how to build it into a practice already serving this patient.
63% of patients on GLP-1 medications are new to aesthetics — and they’re arriving with a distinct presentation that requires a different clinical and business approach. Here’s what GLP-1 aesthetic patients actually need from their provider, and how to build a practice model that serves them well.
Exosome therapy is showing up on practice menus faster than providers can vet the regulatory risk. Before you add it to your aesthetic practice, here’s what FDA enforcement in 2026 actually means for you.
April’s clinical and business signals point in the same direction: the practices growing most consistently right now are those expanding their definition of who their patient is. From menopausal skin protocols to GLP-1 consult frameworks and wellness integration strategies, this month’s update covers what to implement now and what to keep on your radar.
April 2026 brought a wave of regulatory and clinical developments that GLP-1 providers need to act on before summer. From a landmark FDA compounding proposal to the Medicare GLP-1 Bridge program’s July 1 launch, here is what changed and what it means for your practice.
Building a profitable aesthetic practice requires more than clinical skill — it requires understanding the unit economics, patient lifetime value, and retention strategies that separate high-performing practices from the rest. This article breaks down the financial architecture behind sustainable aesthetic medicine, from service mix margins to evidence-based retention data.
A recombinant botulinum toxin type A called YY001 recently completed a Phase III trial showing favorable efficacy and safety results compared to onabotulinumtoxinA for glabellar lines. While the product is not available in the United States, understanding how recombinant toxins differ from traditional formulations helps aesthetic providers evaluate emerging data and marketing claims.